Table 2 Completeness of data, agreement and correlation for re-abstracted variables concerning diagnostics, surgery, tumor characteristics and treatment from the BCQR
Complete records* in registry, number (%) | Complete records* in medical records, number (%) | Complete records* in both registry and medical records, number (%) | Exact agreement between registry and medical records, number (%) (95% CI) | Correlation or Cohen’s kappa** (95% CI) | |
|---|---|---|---|---|---|
Laterality | 731 (97.9%) | 718 (96.1%) | 703 (94.1%) | 694 (98.7%) (97.6–99.3%) | 0.97 (C) (0.96–0.99) |
Type of breast surgery | 735 (98.4%) | 746 (99.9%) | 734 (98.3%) | 703 (95.8%) (94.1–97.0%) | 0.91 (C) (0.88–0.94) |
Number of investigated lymph nodes | 708 (94.8%) | 741 (99.2%) | 706 (94.5%) | 641 (90.8%) (88.4–92.8%) | 0.96 (P) (0.95–0.96) |
Number of metastatic lymph nodes | 705 (94.4%) | 707 (94.6%) | 699 (93.6%) | 675 (96.6%) (94.9–97.7%) | 0.98 (P) (0.97–0.98) |
Tumor size (mm) | 742 (99.3%) | 736 (98.5%) | 733 (98.1%) | 659 (89.9%) (87.4–91.9%) | 0.90 (P) (0.89–0.92) |
Chemotherapy | 747 (100%) | 741 (99.2%) | 741 (99.2%) | 688 (92.8%) (90.8–95.0%) | 0.84 (C) (0.80–0.88) |
Endocrine therapy | 747 (100%) | 740 (99.1%) | 740 (99.1%) | 671 (90.7%) (88.4–92.6%) | 0.81 (C) (0.77–0.85) |
Tamoxifen | 747 (100%) | 737 (98.7%) | 737 (98.7%) | 647 (87.8%) (85.0–90.0%) | 0.76 (C) (0.71–0.80) |
Aromatase inhibitor | 747 (100%) | 736 (98.5%) | 736 (98.5%) | 638 (86.7%) (84.0–89.0%) | 0.50 (C) (0.41–0.58) |
Anti-HER2 therapy | 747 (100%) | 738 (98.8%) | 738 (98.8%) | 727 (98.5%) (97.0–99.0%) | 0.71 (C) (0.55–0.87) |
Radiotherapy | 747 (100%) | 741 (99.2%) | 741 (99.2%) | 692 (93.4%) (91.0–95.0%) | 0.81 (C) (0.76–0.86) |